

**This student paper was written as an
assignment in the graduate course**

Free Radicals in Biology and Medicine

(77:222, Spring 2003)

offered by the

Free Radical and Radiation Biology Program

B-180 Med Labs

The University of Iowa

Iowa City, IA 52242-1181

Spring 2003 Term

Instructors:

GARRY R. BUETTNER, Ph.D.

LARRY W. OBERLEY, Ph.D.

with guest lectures from:

Drs. Freya Q . Schafer, Douglas R. Spitz, and Frederick E. Domann

The Fine Print:

Because this is a paper written by a beginning student as an assignment, there are no guarantees that everything is absolutely correct and accurate.

In view of the possibility of human error or changes in our knowledge due to continued research, neither the author nor The University of Iowa nor any other party who has been involved in the preparation or publication of this work warrants that the information contained herein is in every respect accurate or complete, and they are not responsible for any errors or omissions or for the results obtained from the use of such information. Readers are encouraged to confirm the information contained herein with other sources.

All material contained in this paper is copyright of the author, or the owner of the source that the material was taken from. This work is not intended as a threat to the ownership of said copyrights.

Desferrioxamine (DFO)

By

Ling Xiao

B-180 Medical Laboratories

Free Radical and Radiation Biology program

The University of Iowa

Iowa City, IA 52242-1181

For 77:222, Spring 2003

Due Date: Feb 17, 2003

Abbreviations

DFO, desferrioxamine, Desferal[®]

O_2^- , superoxide

HO^{\cdot} , hydroxyl radical

ESR, electron spin resonance

Table of contents	Page number
Abstract	2
Introduction	3
Structure of DFO	3
Physical and chemical properties of DFO	4
Iron(III) chelator	4
The mechanisms of DFO in preventing iron overloading diseases	5
Formation of the nitroxide radical of DFO	7
Summary	9
References	10

Abstract

Desferrioxamine (DFO) is a strong Fe(III) chelator, and is used clinically to treat iron overload diseases. DFO acts as antioxidant to prevent damage caused by superoxide anion or hydroxyl radicals. The primary mechanisms of DFO antioxidant role is that DFO forms a complex with Fe(III) to inactivate Fe(III), thus inhibiting the potential to generate HO[·] via the Fenton reaction. Furthermore, DFO can directly react with superoxide anion and hydroxyl radical to act as a free radical scavenger. However, DFO can produce nitroxide free radical through one-electron oxidation reaction, and hence cause lipid peroxidation and enzyme inactivation, especially at high concentrations. This nitroxide free radical has been identified by electron spin resonance (ESR). And efforts have been given to generate other DFO derivatives without the toxicity while keeping iron chelating ability. This review focuses on the biochemical properties and the mechanisms of DFO as an agent in treating iron overloaded diseases as well as the biological relevant of DFO.

Introduction

Desferrioxamine (DFO) is a hydroxamate type of siderophore derived from the microorganism, *Streptomyces pilosus* [1]. It is available as Desferal[®], a commercial name for the methanesulfonate salt of DFO. DFO has a high affinity and specificity for ferric iron and is used clinically to treat iron overload diseases such as acute iron poisoning and β -thalassemia [2]. The $O_2^{\cdot-}$ can be formed in almost all aerobic organisms and HO^{\cdot} can be generated from $O_2^{\cdot-}$ together with H_2O_2 via the Haber-Weiss reaction, which usually requires iron as a catalyst [3]. DFO has been shown to be able to inhibit this reaction, thus blocking generation of HO^{\cdot} from $O_2^{\cdot-}$ by forming a unreactive DFO-Fe(III) complex [4]. Furthermore, DFO was shown to be an HO^{\cdot} scavenger [5]. However, DFO has been shown to promote lipid peroxidation at high concentration through interaction between DFO and $O_2^{\cdot-}$ and HO^{\cdot} to form the DFO nitroxide radical, which caused some damages to the cells [6, 7]. Nevertheless, DFO is still a very useful agent to treat iron overload diseases. This review focuses on the structure, chemical reactivity, and biological relevance of DFO.

Structure of DFO

DFO is the principal product of the various sideramines obtained from *Streptomyces pilosus* [1]. DFO consists of one molecule of acetic acid, two molecules of succinic acid, and three molecules of 1-amino-5-hydroxylamino-pentane (Figure 1, adapted from [1]). The organic units of DFO are interlinked to form a chain, in which three hydroxamic groups are inside and one free amino group at the end. The free amino group is capable of reacting with organic and inorganic acids to form DFO salts.

1Mol $\text{CH}_3\text{-COOH}$ Acetic Acid

2Mol $\text{HOOC-(CH}_2\text{)}_2\text{-COOH}$ Succinic acid

3Mol $\text{NH}_2\text{-(CH}_2\text{)}_5\text{-NH}_2$ 1,5-Diaminopentane




FIGURE 1. Desferrioxamine B.

Physical and chemical properties of DFO

DFO is colorless and water-soluble substance, which reacts slightly with alkali. DFO remains stabilized for eighty-four hours in a buffer solution at pH 6.1, but decomposes slowly at rate of 10% in fourteen hours in a buffer at pH 1.1. If it incubated with gastric juice of pH 2.5 at 37 °C, it disintegrates at the rate of 4% h⁻¹. DFO has a molecular weight of 597 Da, and 1 molecule binds 1 molecule of Fe(III) ions [8]. DFO can act as scavenger of HO[·] and O₂^{·-} [5]. Paradoxically, DFO has been shown to promote lipid peroxidation, especially at high doses [6].

Iron(III) chelator

DFO is a very strong and specific iron(III) chelator. The stability constants for various DFO-metal complexes compared with other chelating agents are listed in table 1. The higher the stability constant is, the more stable the complex is. The highest constant is 10³¹, which is for iron(III)-DFO complex. DFO showed no significant affinity to ferrous ions.

Adapted from [1].



TABLE 1
STABILITY CONSTANTS OF SOME CHELATING AGENTS

Metallic ion	Desferrioxamine	EDTA	DTPA	Transferrin
Fe ³⁺	10 ³¹	10 ²⁵	10 ²⁹	10 ²⁷ ; 10 ²⁹
Ca ²⁺	10 ²	10 ¹¹	10 ¹⁰	
Mg ²⁺	10 ⁴	10 ⁹	10 ⁹	
Sr ²⁺	10	10 ⁹	10 ¹⁰	
Zn ²⁺	10 ¹¹	10 ¹⁶		
Ni ²⁺	10 ¹⁰	10 ¹⁹	10 ²⁰	
Co ²⁺	10 ¹¹	10 ¹⁶	10 ¹⁹	
Cu ²⁺	10 ¹⁴			
Fe ²⁺	~ 10 ¹⁰			

The mechanisms of

DFO in preventing iron overloading diseases

The generated $O_2^{\cdot -}$ in the cell has many deleterious effects, and in presence of H_2O_2 , it will give rise to the highly reactive HO^{\cdot} . There is no evidence that $O_2^{\cdot -}$ will react directly with H_2O_2 , but in presence of iron salt will results in HO^{\cdot} through following reactions [3]:



DFO twines itself around the iron and attaches to the latter by means of its three hydroxamic acid groups to form ferrioxamine complex (Figure 2). The iron is surrounded by a shell of organic material, and this complex is very stable and cannot undergo redox cycling, thus preventing iron-

catalyzed OH[·] formation or lipid peroxidation [4].




Figure 2. The schematic structure of DFO-Fe(III) complex (adapted from [1]).

Furthermore, it was shown that DFO could act as a scavenger of HO[·] and O₂^{·-} to inhibit oxygen-mediated damage [6, 7]. HO[·] reacts rapidly with thiocyanate to produce [·](SCN)₂⁻. By observing the ability of DFO and ferrioxamine to compete with thiocyanate for HO[·], rate constants for their reaction with this radical can be determined [5]. Figure 3A shows a typical result for DFO and Figure 3B shows a result for ferrioxamine [5]. From duplicate experiments rate constants for the reaction of both compounds with HO[·] were found to be $(1.3 \pm 0.1) \times 10^{10} \text{ M}^{-1} \text{ s}^{-1}$, indicating that they are powerful scavengers of HO[·] [5]. And reaction of ferrioxamine with HO[·] led to release of Fe(III) from the DFO-Fe(III) complex [5]. And this process followed first order kinetics and was independent of the rate of initial reaction [5].

In addition, DFO was also able to react with O₂^{·-} generated by the action of xanthine oxidase on xanthine to act as scavenger of O₂^{·-} [8]. And the rate constant of the reaction between DFO and O₂^{·-} is approximately $1.3 \times 10^6 \text{ dm}^3 \text{ mol}^{-1} \text{ s}^{-1}$ at physiological pH [9].




Figure 3. Determination of rate constant for the reaction of DFO and ferrioxamine by competition with thiocyanate. The absorbances at 480 nm of irradiated thiocyanate solution with (A) and without (A°) DFO and ferrioxamine was measured and are related by the equation

$$A^\circ/A = 1 + K_c/K_t \times [\text{chelator}]/[\text{thiocyanate}]$$

Thus plotting A°/A against the ratio of concentrations allows calculations of the rate constant K_c . K_t is taken as $1.1 \times 10^{10} \text{ M}^{-1} \text{ s}^{-1}$. Plot (A) shows data for DFO and plot (B) for ferrioxamine.

Formation of the nitroxide radical by DFO

In spite of the antioxidant roles of DFO, the prolonged clinical use of DFO is far from benign. And paradoxically, DFO has been shown to promote lipid peroxidation at higher concentration [10]. The toxicity might be due to the formation of DFO radicals. This nitroxide free radical from DFO can be produced by various peroxidases, or by ionizing, or UV irradiation [11, 12]. The following diagram shows the formation of a nitroxide radical of DFO (Figure 4). It should be noted that DFO has three hydroxamic acid groups and due to the structural similarities of the environment surrounding the nitroxide groups, it is not possible to determine which hydroxamic acid group of DFO is under attack. Thus, the scheme shows one possible radical structure that produces the spectrum they observed [13]. Furthermore, the DFO nitroxide radical

formed from the interaction between DFO and superoxide anion and hydroxyl radical has been shown to inactivate alcohol dehydrogenase [12].




Figure 4. Diagram showing one possible form of a DFO nitroxide radical [13].

This nitroxide radical of DFO is the one-electron oxidation product of DFO, which has been successfully identified by electron spin resonance (ESR) (Figure 5). The oxidation of Desferal leads to a stable nitroxide free radical with a g factor of 2.0065. An acetyl nitroxide nitrogen coupling ($a^N = 7.85$ G) is split by two protons ($a^H = 6.35$ G) from a neighboring CH_2 group [6].




Figure 5. ESR spectrum of the nitroxide free radical obtained upon reaction of the hydroxyl radical with DFO [6]. (A) Photolysis of a 0.1 mM hydrogen peroxide solution containing 1 mM Desferal in 100 mM phosphate buffer (pH 7.4). (B) Same as A, but in the absence of Desferal. (C) Same as A, but without H₂O₂ added. (D) Same as A, but with lamp off. Spectrometer settings: microwave power, 21 mW; modulation amplitude, 0.53 G; sweep rate, 0.1 G/s; time constant, 2 s.

Summary

DFO has high affinity and specificity for Fe(III). It is used major in iron overloading diseases clinically. DFO play antioxidant role by direct chelating Fe(III) and superoxide anion and hydroxyl radical scavenger. But it has some cytotoxicity due to the nitroxide free radical from one electron oxidation of DFO. And it is not very clear whether this nitroxide radical is generated *in vivo*.

Reference

1. Keberle, H. (1964) The biochemistry of desferrioxamine and its relation to iron metabolism. *Annals New York Acad Sci* **119**:758-768.
2. Modell, B., Ketsjy, E. A., Flynn, D. M., Peto, R., Weatherall, D. J. (1982) Survival and desferrioxamine in thalassaemia major. *Br Med J* **284**:1081-1087.
3. Graf, E., Mahoney, J. R., Bryant, R. G. (1980) Iron-catalyzed hydroxyl radical formation: stringent requirement for free iron coordination site. *J Biol Chem* **259**:3620-3624.
4. Gutteridge, J., Richmond, R., Halliwell, B. (1979) Inhibition of the iron-catalyzed formation of hydroxyl radicals from superoxide and of lipid peroxidation by desferrioxamine. *Biochem J* **184**:469-472.
5. Hoe, S., Rowley, D. A., Halliwell, B. (1982) Reaction of ferrioxamine and desferrioxamine with the hydroxyl radical. *Chem Biol Interactions* **41**:75-81.
6. Morehouse, K. M., Flitter, W. D., Mason, R. P. (1987) The enzymatic oxidation of desferal to a nitroxide free radical. *FEBS Letters* **22**:246-250
7. Soriani, M., Massuca, S. A., Quaresima, V., Minetti, M. (1993) Oxidation of desferrioxamine to nitroxide free radical by activated human neutrophils. *Free Radical Biol Med* **14**:589-599.
8. Sinaceur, J., Ribiere, C., Nordmann, J., Nordmann, R. (1983) Desferrioxamine: a scavenger of superoxide radicals? *Biochem Pharma* **33**:1693-1694.
9. Sabourault, D., Ribiere, C., Nordmann, R., Houee-Levin, C., Ferradini, C. (1989) Gamma and pulse radiolysis investigation of the reaction of desferrioxamine with superoxide anions. *Int J Radiat Biol* **56**:911-921.
10. Braughler, J. M., Chase, R. L., Pregoner, J. (1988) Stimulation and inhibition of iron-dependent lipid peroxidation by desferrioxamine. *Biochem Biophys Res Commun* **153**:933-938.
11. Hinojosa, O., Jacks, J. T., Calamari, T. A. (1989) Electron spin resonance study of the relationship of UV irradiation to nitroxide radical formation in desferrioxamine (desferal) and related hydroxamate and hydroxylamine derivatives. *Photochem Photobiol* **49**:1-5.
12. Davies, M. J., Donkor, R., Dunster, C. A. (1987) Desferrioxamine (Desferal) and superoxide free radicals. *Biochem J* **246**:725-729.
13. Pieper, G. M., Gross, G. J., Kalyanaraman, B. (1990) An ESR study of the nitroxide radical of pentastarch-conjugated desferrioxamine. *Free Radical Biol Med* **9**:211-218.